Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MLYCD | O95822 | 1/20 | 0.68 |
| ▸ | TAS1R3 | Q7RTX0 | 14/20 | 0.63 |
| ▸ | TAS1R1 | Q7RTX1 | 13/20 | 0.63 |
| ▸ | TAS1R2 | Q8TE23 | 12/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | CA12 | O43570 | 1/20 | 0.56 |
| ▸ | CA1 | P00915 | 1/20 | 0.56 |
| ▸ | CA9 | Q16790 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889027 | 0.97 | MLYCD (0.63) | MLYCDTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL517994 | 0.92 | MLYCD (0.77) | MLYCDTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL889096 | 0.90 | MLYCD (0.55) | MLYCDTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL517895 | 0.87 | MLYCD (0.71) | MLYCDTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL4175029 | 0.86 | TAS1R3 (0.72) | MLYCDTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL13927736 | 0.86 | TAS1R3 (0.72) | MLYCDTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL13927734 | 0.86 | TAS1R3 (0.72) | MLYCDTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL95611 | 0.84 | MLYCD (0.68) | MLYCDTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL20712985 | 0.84 | MLYCD (0.67) | MLYCDTAS1R3TAS1R1TAS1R2ALDH1A1 | |
| SCHEMBL9691775 | 0.84 | MLYCD (0.67) | MLYCDTAS1R3TAS1R1TAS1R2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8822700-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-8815928-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-08-26 | — | — | US | disclosed |
| US-8759332-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| US-8703938-B2 | Hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-24 | — | — | US | disclosed |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110064697-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | MLYCD 2777/4885TAS1R3 4542/4885TAS1R1 4560/4885 |
| US-20110064695-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | MLYCD 2777/4885TAS1R3 4542/4885TAS1R1 4560/4885 |
| US-20110064696-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | MLYCD 2777/4885TAS1R3 4542/4885TAS1R1 4560/4885 |
| US-20110070197-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, EIF2AK2, SLC10A1 | MLYCD 2777/4885TAS1R3 4542/4885TAS1R1 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.